Yamagata, Hirotaka
Ogihara, Hiroyuki
Matsuo, Koji
Uchida, Shusaku
Kobayashi, Ayumi
Seki, Tomoe
Kobayashi, Masaaki
Harada, Kenichiro
Chen, Chong
Miyata, Shigeo
Fukuda, Masato
Mikuni, Masahiko
Hamamoto, Yoshihiko
Watanabe, Yoshifumi
Nakagawa, Shin
Funding for this research was provided by:
“Integrated Research on Neuropsychiatric Disorders” conducted under the Strategic Research Program for Brain Sciences from the MEXT and AMED
the JSPS KAKENHI (16K10189)
the Industrial Strategic Research and Development from the Yamaguchi Prefecture
SENSHIN Medical Research Foundation
the Core Research for Evolutional Science and Technology
Article History
Received: 2 May 2020
Accepted: 11 January 2021
First Online: 27 January 2021
Competing interests
: The authors report here all financial or other relationships that are relevant to the subject of this article. H.Y. has received a research grant from Pfizer, Eisai, and MSD. K.M. has received honoraria from Meiji Seika Pharma, Kyowa Pharmaceutical Industry, Mochida Pharmaceutical, Eli Lilly, Janssen Pharmaceutical K.K., and Pfizer. S.N. has received honoraria and/or research grant support from Otsuka Pharmaceutical, Meiji Seika Pharma, Sumitomo Dainippon Pharma, Kyowa Pharmaceutical Industry, Shionogi, Mitsubishi Tanabe Pharma, Mochida Pharmaceutical, Eisai, Tsumura, Eli Lilly, MSD, Astellas, and Pfizer. The other authors declare no actual or potential conflict of interest.